PFE
$26.61
Pfizer Inc.
Intraday
Recent News
BioNTech Stock Is a Bargain. Why Its Recent Selloff Is a Buying Opportunity.
The company’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.
GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger Adults
GSK secures FDA approval to expand Arexvy's use to high-risk adults aged 18-49 years, broadening access as the company pushes wider global adoption.
Pfizer Trials Highlight Effort To Broaden Future Revenue And Defend Franchises
Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing flexibility and cost-efficiency. The company has initiated a Phase 2 pediatric trial of etrasimod in ulcerative colitis and a Phase 1 trial for a next generation oncology candidate. Pfizer has completed a Phase 2 study of its multivalent pneumococcal vaccine candidate PG4, with data analysis underway. These updates provide a fresh look at how Pfizer, best known recently for...
Is Zoetis Inc. (ZTS) A Good Stock To Buy Now?
Is ZTS a good stock to buy now? We came across a bullish thesis on Zoetis Inc. on Rebound Capital’s Substack. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $131.10 as of February 27th. ZTS’s trailing and forward P/E were 21.78 and 19.08 respectively according to Yahoo Finance. Zoetis […]
Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $26.81 as of March 9th. PFE’s trailing and forward P/E were 19.89 and 9.14, respectively according to Yahoo Finance. Pfizer Inc. […]